This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
All content for Centeno-Schultz Clinic - Podcasts is the property of Centeno-Schultz Clinic Staff and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
Why Most People with a Retroflexed Dens Don't Need Surgery
Centeno-Schultz Clinic - Podcasts
1 hour 4 minutes
3 days ago
Why Most People with a Retroflexed Dens Don't Need Surgery
Dr. Centeno discusses how the presence of a retroflexed dens on an MRI doesn't mean that it's causing symptoms. He reviews research on this topic and discusses how a retroflexed dens plus CCI or craniocervical instability can cause symptoms. https://youtube.com/live/8j2qbOAaDdE
Centeno-Schultz Clinic - Podcasts
This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
